归肾丸的现代应用及研究现状

通过对古方归肾丸在妇科疾病如月经不调、不孕症、卵巢早衰等的治疗作用和实验研究进展的综述,揭示古方新用治疗妇科生殖内分泌疾病的概况及作用机制。     

中药药性理论研究模式的新思路

基于古今文献资料,分析了现有药性理论研究的现状与存在问题.广义中药药性即四气、五味、归经,升、降、浮、沉等性能的认知基于功效与主治病证(应用),而功效术语表达又是药性的综合再现,可见“性—效—用”密切关联;中药的品种、质量是产生“性—效—用”的前提条件.提出按中药功效分类,依循“品—质—性—效—用”为路径的综合研究模式,在中医药理论指导下,以脏腑辨证为核心,以寒热辨证为纲要,设定药性整体与效应关联的观测指标,融合多学科知识,采用多种现代技术,开展系统、深入的多维研究,探寻基于功效分类的药性理论现代科学内涵.     

急性缺血性脑卒中患者肾功能状况及其相关因素的研究

目的 探讨急性缺血性脑卒中住院患者肾功能状况及肾功能下降患者的临床特征.方法 选择2009年6～11月慈溪市人民医院神经内科住院的87例缺血性脑卒中患者,以MDRD公式计算肾小球滤过率,将eGFR＜ 90 mL/（min·1.73 m2）定义为GFR下降,分析GFR下降患者的临床特征.结果 87例患者中GFR下降者有47例（54.02%）,其中eGFR ＜ 60 mL/（min·1.73 m2）6例（6.90%）.GFR下降组患者发病年龄、高血压患病率、颈动脉内膜中层厚度、硬化斑块指数均显著高于GFR正常组（P ＜ 0.05）.回归分析显示,年龄、高血压病史是急性缺血性脑卒中患者GFR下降的独立影响因素.结论 急性缺血性脑卒中患者伴GFR下降的比例较高,GFR下降组患者合并的血管危险因素更多.     

快速康复外科理念在心脏外科手术护理中的应用

目的:在心脏外科手术护理工作中应用快速康复外科理念,探析其临床应用效果.方法:选择2015年6月~2017年6月我院66例行心脏外科手术的患者,随机将其分为对照组与观察组,每组均有患者33例,对照组33例行心脏外科手术常规护理干预方式,观察组33例在对照组患者常规护理干预的基础上实行快速康复外科理念的相关护理干预方式,对比两组患者的临床护理效果.结果:两组患者的住院时间、拔管时间,两组患者各项结果对比差异均比较明显,具有统计学意义,P<0.05.结论:在心脏外科手术护理工作中实施快速康复外科理念的护理方式,有助于改善患者术后各项症状,有效缩短了患者的住院时间和拔管时间,值得推广应用.     

自制股动脉压迫带的应用

自制股动脉压迫带的应用黑龙江省医院杨玉杰，高毅，黄立华随着介入医学的发展，各种血管造影遂年增加，我院十几年来已开展；脑、胸、腹及四肢血管造影。一般采用股动脉插管法（Ｓｅｌｌｄｘｇｅｒ），但拔管后如何处理好穿刺部位，防止出血、感染，合并症的发生，是护理...     

苏合香不同提取方法的气相色谱-质谱研究

目的考察苏合香不同提取方法的化学成分异同。方法应用气相色谱-质谱联用技术,分析比较溶剂提取部位(石油醚和乙醚提取)、水蒸气蒸馏提取挥发油、顶空固相微萃取挥发性成分的异同。结果苏合香溶剂提取鉴定出27个化合物(其中石油醚部位23个化合物、乙醚部位10个化合物),水蒸气蒸馏提取的挥发油鉴定出42个化合物,顶空固相微萃取鉴定出28个化合物。3种方法所得成分中皆含有α-蒎烯、莰烯、Bornyl Cinnamate 2和马苄烯酮等10种化学成分,溶剂提取与水蒸气蒸馏所得的成分中有14种相同成分,水蒸气蒸馏提取与顶空固相微萃取有24个相同成分。结论 3种提取方法中,水蒸气提取法所得成分最多,提示该法可作为获取苏合香挥发性成分的主要方法。     

浅谈基层医院手术室消毒隔离管理

目的：探讨基层医院手术室消毒隔离管理,防止手术室院内感染。方法：通过对手术室空气、手术物品、手术人员的消毒隔离管理,一次性医疗用品的管理及手术后污物的处理等五个方面的控制管理。结果：进一步把好手术室院内感染控制关,确保手术的顺利进行,降低伤口感染率,提高手术治愈率。     

危急值报告在心血管CCU病房的管理体会

<正>随着对医院患者安全目标的管理,我心内科重症病房结合医院危急值管理,制定科室特色危急值管理程序,对于减少不良医疗及护理事件起到重要作用,但还有不足,需要进一步完善。危急值(Critical Values)是指某项或某类检验异常结果,而当这种检验异常结果出现时,表明患者可能正处于有生命危险的边缘状态,临床医生需要及时得到检验信息,迅速给予患者有效的干预措施或治疗,就可能挽救患者生命,否则就     

舒尼替尼治疗转移性肾癌的疗效和安全性分析:单中心37例总结

Objective To evaluate the efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma (RCC). Methods A total of 37 patients with metastatic RCC were treated with between June 2008 and April 2010, including 28 males and 9 females. The median age was 52 (17-74) years. All patients received a pathologic diagnosis of RCC, which consisted of 1 papillary cell carcinoma and 36 clear cell carcinomas, 4 of which accompanied with partial sarcoma differentiation. Thirty cases were treated with first line therapy and 7 cases showed progression on first-line cytokine or sorafinib therapy. Sunitinib monotherapy was administered in repeated 6-week cycles of daily oral therapy for 4 weeks, followed by 2 weeks off in 34 patients, while another 3 patients received 37. 5 mg Qd continuously until disease progression or unacceptable toxicities occurred. Overall response rate and safety were evaluated. Results The median follow up was 12 months (8 cycles),range 1.5-19. 5 months (1-13 cycles). 26.5% (9/34) patients achieved partial responses, 70.6%(24/34) patients demonstrated stable disease over≥3 months and 1 (2. 9%) patient developed progressive disease. The objective response rate was 26.5%, and the disease control rate was 97. 1%.The 12 months' overall survival rate was 95.8% (23/24), and 12 months' progression-free survival rate was 62.5 % (15/24). The most common treatment-related adverse events were thrombocytopenia (30 cases, 81.1%), thyroid dysfunction (18/22, 81.8%) ,hand-foot syndrome (27 cases, 73.0%),neutropenia (23 cases, 62.2%) and hypertension (18 cases, 48.6%). The major grade 3 adverse events included thrombocytopenia (8 cases, 21.6%), hand-foot syndrome (4 cases, 10.8%) and diarrhea (2 cases, 5. 4%). Most adverse events were ameliorated by treatment interruption. Ten (27.0%) patients had dose decrement or drug discontinuation and 1 patient quit the treatment for intolerable fatigue. Conclusion The efficacy and manageable adverse event profile of sunitinib as a single agent in first- or second-line therapy for patients with metastatic RCC.     

舒尼替尼治疗转移性肾癌的疗效和安全性分析:单中心37例总结

Objective To evaluate the efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma (RCC). Methods A total of 37 patients with metastatic RCC were treated with between June 2008 and April 2010, including 28 males and 9 females. The median age was 52 (17-74) years. All patients received a pathologic diagnosis of RCC, which consisted of 1 papillary cell carcinoma and 36 clear cell carcinomas, 4 of which accompanied with partial sarcoma differentiation. Thirty cases were treated with first line therapy and 7 cases showed progression on first-line cytokine or sorafinib therapy. Sunitinib monotherapy was administered in repeated 6-week cycles of daily oral therapy for 4 weeks, followed by 2 weeks off in 34 patients, while another 3 patients received 37. 5 mg Qd continuously until disease progression or unacceptable toxicities occurred. Overall response rate and safety were evaluated. Results The median follow up was 12 months (8 cycles),range 1.5-19. 5 months (1-13 cycles). 26.5% (9/34) patients achieved partial responses, 70.6%(24/34) patients demonstrated stable disease over≥3 months and 1 (2. 9%) patient developed progressive disease. The objective response rate was 26.5%, and the disease control rate was 97. 1%.The 12 months' overall survival rate was 95.8% (23/24), and 12 months' progression-free survival rate was 62.5 % (15/24). The most common treatment-related adverse events were thrombocytopenia (30 cases, 81.1%), thyroid dysfunction (18/22, 81.8%) ,hand-foot syndrome (27 cases, 73.0%),neutropenia (23 cases, 62.2%) and hypertension (18 cases, 48.6%). The major grade 3 adverse events included thrombocytopenia (8 cases, 21.6%), hand-foot syndrome (4 cases, 10.8%) and diarrhea (2 cases, 5. 4%). Most adverse events were ameliorated by treatment interruption. Ten (27.0%) patients had dose decrement or drug discontinuation and 1 patient quit the treatment for intolerable fatigue. Conclusion The efficacy and manageable adverse event profile of sunitinib as a single agent in first- or second-line therapy for patients with metastatic RCC.